Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Baylor College of Medicine
52 participants
Feb 15, 2022
INTERVENTIONAL
Conditions
Summary
Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
The placebo arm will supplement Alanine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04740580